Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen–Negative Patients

Stopping long-term nucleos(t)ide analogue therapy increases hepatitis B virus (HBV) surface antigen (HBsAg) loss rates in HBV e antigen (HBeAg)-negative patients. Viral rebound may induce immune responses facilitating functional cure. We analyzed which factors are associated with timing of virological relapse in 220 Asian HBeAg-negative patients from the prospective ABX203 vaccine study. Unexpectedly, only the type of antiviral therapy was significantly associated with early virological relapse, defined as an HBV DNA load of >2000 IU/mL until week 12, and relapse occurred earlier in patients treated with tenofovir versus those treated with entecavir (median time, 6 vs 24 weeks; P < .0001). This should be considered for future trials and monitoring of patients after treatment discontinuation.

• Publication year

  2018

• Venue

  Journal of Infectious Diseases

• Publication date

  2018-06-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/infdis/jiy350PMID 29893893
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen–negative chronic hepatitis B

  2018cited by this paper
• Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy

  2018cited by this paper
• Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss

  2018cited by this paper
• Therapeutic vaccination of chronic hepatitis B patients with ABX203 (NASVAC) to prevent relapse after stopping NUCs: contrasting timing rebound between tenofovir and entecavir

  2017cited by this paper
• Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.

  2017cited by this paper
• EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

  2017cited by this paper
• AASLD guidelines for treatment of chronic hepatitis B

  2016cited by this paper
• Discontinuation of oral antivirals in chronic hepatitis B: A systematic review

  2016cited by this paper
• Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B.

  2016cited by this paper
• Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection

  2016cited by this paper
• Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

  2015cited by this paper
• Off‐therapy durability of response to entecavir therapy in hepatitis B e antigen‐negative chronic hepatitis B patients

  2013cited by this paper
• Entecavir Pharmacokinetics, Safety, and Tolerability After Multiple Ascending Doses in Healthy Subjects

  2006cited by this paper
• American Association for the Study of Liver Diseases

  1959cited by this paper

• The effect of treatment cessation on HBsAg negativity in HBeAg-negative chronic hepatitis B patients treated with nucleos(t)id analogues for more than three years

  2026cites this paper
• Long-term HBsAg clearance, relapse, and safety following tenofovir or entecavir discontinuation in non-cirrhotic, HBeAg-negative chronic hepatitis.

  2026cites this paper
• Switching to entecavir >3 months before the end of tenofovir-based therapy in HBeAg-negative patients may reduce early relapse and hepatitis flare.

  2025cites this paper
• Steatosis and Interferon Associated with HBsAg Immune Control in Chronic Hepatitis B: A Real-World Propensity Score-Matched Study

  2025cites this paper
• Scoping Review on Strategies for Safe Nucleot(s)ide Analogue Discontinuation and Optimising Functional Cure in Chronic Hepatitis B

  2025cites this paper
• Hepatitis B Surface Antigen Seroclearance Rate After Stopping Nucleos(t)ide Analogues in Chronic Hepatitis B—A Systematic Review and Meta‐Analysis

  2025influential citation
• EASL Clinical Practice Guidelines on the management of hepatitis B virus infection.

  2025cites this paper
• Anti-HBs immune complex levels: A novel marker of hepatitis flare following nucleos(t)ide analogue withdrawal in HBeAg-negative chronic hepatitis B.

  2025cites this paper
• Evaluation of chronic hepatitis B patients who voluntarily discontinued oral antiviral therapy: is there an answer to the controversial topic?

  2024cites this paper
• THE IMPACT OF PREMATURE DISCONTINUATION OF ANTIVIRAL THERAPY IN CHRONIC HEPATITIS B : A CASE REPORT

  2024cites this paper
• HeberNasvac: Development and Application in the Context of Chronic Hepatitis B

  2024cites this paper
• Limited Value of HBV‐RNA for Relapse Prediction After Nucleos(t)ide Analogue Withdrawal in HBeAg‐negative Hepatitis B Patients

  2024cites this paper
• Discontinuation of Nucleos(t)ide Analogues in HBeAg Negative Chronic Hepatitis B Patients: Risks and Benefits

  2024cites this paper
• Risk factors for relapse after discontinuation of tenofovir or entecavir in hepatitis B e antigen-negative patients

  2024cites this paper
• When to Stop Antiviral Therapy in HBeAg-Negative Patients with Chronic Hepatitis B?

  2024cites this paper
• Nucleos(t)ide analogs for hepatitis B virus infection differentially regulate the growth factor signaling in hepatocytes

  2024cites this paper
• Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm

  2023cites this paper
• Treatment cessation in HBeAg-negative chronic hepatitis B: clinical response is associated with increase in specific proinflammatory cytokines

  2023cites this paper
• Prediction of clinical relapse and HBsAg loss after cessation of anti-HBV therapy.

  2023cites this paper
• HBV relapse rates in patients who discontinue tenofovir disoproxil fumarate with or without switching to tenofovir alafenamide.

  2023cites this paper
• Editorial: is functional cure the only holy grail for treatment discontinuation in patients with HBeAg‐negative chronic hepatitis B?

  2022cites this paper
• Clinical Utility of SCALE-B to Predict Hepatitis B Virus Relapse, Hepatitis B Surface Antigen Loss After Antiviral Cessation in Asian Patients After 2-Year Follow-up

  2022cites this paper
• Stopping nucleot(s)ide analogues in non‐cirrhotic HBeAg‐negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels

  2022cites this paper
• Differential relapse patterns after discontinuation of entecavir vs tenofovir disoproxil fumarate in chronic hepatitis B.

  2022cites this paper
• Distinct relapse patterns between HBeAg-negative patients stopping tenofovir and entecavir.

  2022cites this paper
• Evidence-Based Management of Oral Nucleos(t)ide Analogue Withdrawal in Virally Suppressed Patients with Chronic HBV Infection

  2022cites this paper
• Low anti‐HBc levels are associated with lower risk of virological relapse after nucleos(t)ide analogue cessation in HBe antigen‐negative patients

  2022cites this paper
• Off‐tenofovir hepatitis flares in HBeAg‐negative patients occur earlier, more frequent and severe than those off‐entecavir therapies

  2021cites this paper
• Designing the next‐generation therapeutic vaccines to cure chronic hepatitis B: focus on antigen presentation, vaccine properties and effect measures

  2021cites this paper
• Predictors of successful treatment withdrawal in HBV: unresolved issues.

  2021cites this paper
• Hepatocellular carcinoma after treatment cessation in non‐cirrhotic HBeAg‐negative chronic hepatitis B: A multicentre cohort study

  2021cites this paper
• S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11)

  2021cites this paper
• Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B

  2021cites this paper
• Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis

  2021cites this paper
• APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients

  2021cites this paper
• Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad.

  2020cites this paper
• Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B

  2020cites this paper
• Serum Alanine Aminotransferase Flares In Chronic Hepatitis B: The Good and The Bad

  2020cites this paper
• Cessation of nucleos(t)ide analogues therapy in chronic hepatitis B: a systematic review and meta-analysis

  2020influential citation
• PREDICTION OF SUSTAINED RESPONSE AFTER NUCLEO(S)TIDE ANALOGUE CESSATION USING HBSAG AND HBCRAG LEVELS - A MULTICENTER STUDY (CREATE).

  2020cites this paper
• Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg‐Negative CHB

  2020influential citation
• Views on stopping nucleos(t)ide analogue therapy in patients with chronic hepatitis B.

  2020cites this paper
• Hepatitis B Flare After Cessation of Nucleos(t)ide Analogue Therapy in HBeAg‐Negative Chronic Hepatitis B: To Retreat or Not to Retreat

  2020cites this paper
• Serum HBV RNA Dynamic and Drug Withdrawal Predictor Value in Patients With Chronic HBV Infection on Long-term Nucleos(t)ide Analogue (NA) Therapy

  2020cites this paper
• Evidence-Based Approach to Stopping Oral Antiviral Therapy in Chronic HBV

  2019cites this paper
• Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection

  2019cites this paper
• Updates on Chronic HBV: Current Challenges and Future Goals

  2019cites this paper
• Current state-of-the-art pharmacotherapy for the management of hepatitis B infection

  2019cites this paper
• The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg‐negative chronic hepatitis B

  2019cites this paper
• Liver safety assessment in clinical trials of new agents for chronic hepatitis B

  2019cites this paper
• [New Potential Therapies for Chronic Hepatitis B].

  2019cites this paper
• Reply to Liaw.

  2018cites this paper
• EUR Research Information Portal Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B

  year unknowncites this paper